Sotoxen 120 mg | Generic Sotorasib by Everest Pharmaceuticals

Description

Dr. Daria KwaśniewskaESMO Certified Consultant Medical Oncologist

Reviewed June 2026

⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid oncologist prescription confirming KRAS G12C mutation status is mandatory before any order is processed.

Is Sotoxen 120 mg right for your situation?

Review these criteria with your oncologist before enquiring

✔ You may be a candidate if

✓Locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), confirmed by an FDA-approved test
✓Have received at least one prior systemic therapy
✓Need a WHO-GMP generic alternative to Lumakras® (Amgen)
✓Able to comply with liver function monitoring requirements

✖ May NOT be suitable if

✗KRAS G12C mutation not confirmed by validated testing
✗Significant pre-existing liver disease without close monitoring capability
✗Pregnant, planning pregnancy, or breastfeeding
✗Currently taking proton pump inhibitors or other acid-reducing medications without adjustment plan

Check Availability & Pricing

Prescription required · Named Patient Program · Worldwide shipping

💬 WhatsApp: +880 130 449 8958 ✉ Email: info@medsforcancer.com

🛡 WHO-GMP Certified · Prescription verified · Express dispatch

What is Sotoxen 120 mg?

Sotoxen 120 mg is a generic formulation of Sotorasib — the first-in-class KRAS G12C inhibitor — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 120 mg of sotorasib, the same active molecule found in Lumakras® (Amgen), and is dispensed under the Named Patient Program.

KRAS mutations were considered “undruggable” for decades. Sotorasib was the first therapy to successfully target the KRAS G12C mutation directly, representing a major breakthrough for a subset of NSCLC patients who previously had limited targeted-therapy options.

Generic name	Sotorasib
Reference brand	Lumakras® (Amgen)
Manufacturer	Everest Pharmaceuticals Ltd.
Standard	WHO-GMP Certified
Drug class	KRAS G12C Inhibitor
Dosage form	Tablet — 120 mg
Pack size	56 tablets per pack
Route	Oral · once daily, with or without food
Prescription	Required — oncologist only, KRAS G12C confirmed

How Sotorasib Works

The KRAS G12C mutation locks the KRAS protein in its permanently “on” state, driving continuous growth signalling in cancer cells. This specific mutation occurs in roughly 13% of non-squamous NSCLC cases.

Sotorasib irreversibly and selectively binds to the mutant KRAS G12C protein in its inactive state, locking it there and preventing it from cycling back to its active, growth-signalling form. This mechanism is highly specific to the G12C mutation — it does not affect normal (wild-type) KRAS, which is why genetic confirmation is mandatory before treatment. NCCN guidelines list sotorasib as a subsequent-therapy option for KRAS G12C-positive NSCLC, including a Category 2B recommendation for CNS involvement.

What to Expect: First 30 Days

Before starting: Baseline liver function tests are required, and confirmation of KRAS G12C mutation status via an FDA-approved test is mandatory.
Weeks 1–6: Liver function tests (ALT/AST) are monitored closely — typically every 3 weeks for the first 3 months — since hepatotoxicity is a significant and relatively common risk with this medication.
First 6 weeks: Diarrhoea, nausea, and fatigue are the most commonly reported early side effects. Report any changes in skin/eye colour or unusual fatigue to your oncologist promptly.

Side Effects

Hepatotoxicity is the most clinically significant risk with sotorasib, occurring in a substantial proportion of patients — regular liver monitoring throughout treatment is essential, not optional.

Common · Usually Manageable

Diarrhoea
Nausea, vomiting
Fatigue
Musculoskeletal pain
Cough
Decreased appetite

Serious · Report Immediately

Hepatotoxicity (occurs in a significant proportion of patients)
Interstitial lung disease / pneumonitis
QT interval prolongation (uncommon)

⚠ Call your doctor immediately if you experience:

Yellowing of skin or eyes, dark urine, or unusual fatigue (possible liver injury)
New or worsening breathlessness, cough, or fever (possible pneumonitis)
Severe or persistent diarrhoea

How to Take Sotoxen 120 mg

Standard dose: 960 mg (eight 120 mg tablets) once daily, with or without food. This is a fixed dose — not weight-based.

1
Once daily, same time each day — can be taken with or without food.
2
Swallow tablets whole with water. If unable to swallow, tablets can be dispersed in room-temperature non-carbonated water (not crushed) following your pharmacist’s specific instructions and consumed within 2 hours.
3
Avoid proton pump inhibitors, H2 blockers, and antacids where possible — these reduce sotorasib absorption. If unavoidable, timing must be separated by several hours; discuss with your oncologist.
4
Attend all scheduled liver function tests — these determine whether your dose needs to be reduced or paused.
5
Storage: room temperature, dry place, out of reach of children.

Frequently Asked Questions

Do I need genetic testing before starting Sotoxen?

Yes, this is mandatory. Sotorasib is only effective and approved for patients with a confirmed KRAS G12C mutation, identified through an FDA-approved molecular test on tumour tissue. It does not work for other KRAS mutations or wild-type KRAS.

Why does the dose require 8 tablets?

The approved dose is 960 mg once daily, built from eight 120 mg tablets. This pill burden reflects the approved dosing regimen established in clinical trials; a postmarketing study has explored whether lower doses provide similar efficacy, but 960 mg remains the FDA-confirmed standard dose under accelerated approval.

Why is liver monitoring so frequent?

Hepatotoxicity occurs in a meaningful proportion of patients taking sotorasib, and can range from mild liver enzyme elevation to more serious drug-induced liver injury. Regular blood tests (roughly every 3 weeks initially) allow your oncologist to catch problems early and adjust or pause treatment before serious injury develops.

Why should I avoid acid-reducing medications?

Sotorasib’s absorption is pH-dependent — proton pump inhibitors, H2 blockers, and antacids raise stomach pH and can significantly reduce how much sotorasib your body absorbs, potentially reducing its effectiveness. If you need acid-reducing medication, discuss safe alternatives or timing with your oncologist rather than stopping sotorasib.

How do I order Sotoxen through Meds For Cancer?

Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist’s prescription confirming KRAS G12C mutation status. Our team will verify the prescription, confirm availability and pricing, and arrange secure international shipping under the Named Patient Program.

🛡 Named Patient Program — Regulatory Framework

Meds For Cancer operates as a Named Patient Program (NPP) facilitator. WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription, in countries where the branded product is unavailable or unaffordable.

Clinical References

Skoulidis F, et al. Sotorasib for lung cancers with KRAS p.G12C mutation (CodeBreaK 100). NEJM 2021;384:2371–2381.
FDA Prescribing Information: Lumakras (sotorasib). Amgen, 2024.